News
Sanofi-aventis Establishes Research Collaboration with Harvard University
Sanofi-aventis announced a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientificex change between Harvard University and sanofi-aventis. The...
News
Bharat Biotech Announces Launched Indias First Cell-culture H1N1 Swine Flu Vaccine
Bharat Biotech announced the launch of India?s first indigenously developed cell culture H1N1 swine fluvaccine under the brand name „HNVAC™. HNVAC™ is the only developing world flu vaccine to be manufactured in cell culture, a highly sterile and controlled...
News
FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules
Dr. Reddy’s Laboratories announced that it will be launching Lansoprazole delayed-release capsules (15 mg and 30 mg), a bioequivalent generic version of Prevacid®* Delayed-Release Capsules, in the US market. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA...
News
First HIV diagnostic assay Results Available in Less Than 50 Minutes
Ortho Clinical Diagnostics announced U.S. FDA approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems. This is...
News
Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
Cephalon, Inc.announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA). The GABITRIL REMS consists of a Medication Guide to inform patients...
News
Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc.
Bristol-Myers Squibb Company announced that it has completed its previously announced acquisition of ZymoGenetics, Inc.. As a result of the transaction, ZymoGenetics has become a wholly-owned subsidiary of Bristol-Myers Squibb. Bristol-Myers Squibb initiated on September 10,...
News
BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX for Treatment of Peyronie’s Disease
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has dosed the first subject in the global Phase 3 program of XIAFLEX® (collagenase clostridium histolyticum) for the treatment...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read